1. The central phenotype claim is not evaluated
Sections 3.2–3.6 evaluate validity, uniqueness, novelty, QED, SA, and LeDock scores. None measures whether a generated molecule induces the requested transcriptomic response. QED and SA describe chemical properties; they cannot establish phenotype fidelity. Similarly, a favorable docking score does not establish target modulation, its direction, or a therapeutic cellular effect.
There is also a consequential distribution shift: training uses compound-induced profiles in MCF7, whereas testing conditions on gene knockdown or overexpression profiles (Section 3.1, p. 5). A model that maps chemical responses back to molecules is not automatically able to interpret a genetic perturbation as a realizable drug response. Knockdown need not phenocopy partial pharmacological inhibition, and binding to TP53 or SMAD3 does not show that a compound reproduces overexpression.
I would like an independent phenotype evaluation, such as held-out compound retrieval or generation assessed with a separately validated response predictor, together with shuffled-profile controls. Ideally, a small experimental study would test both the desired response and target engagement. The immediate requirement is to test the claimed biological relationship; it is not to require a complete drug development study. Without such evidence, the conclusions should be limited to molecular generation under transcriptomic and pocket conditioning.
2. The paired dataset and generalization protocol are insufficiently specified
Section 3.1 gives counts for the three source datasets but does not report how many multimodal samples remain after InChIKey matching, how many unique compounds and targets they contain, or how they are divided into training, validation, and test sets. The size of this intersection is critical because it supports the final multimodal fine-tuning stage.
Please report compound-level, scaffold-level, and target/pocket-level overlap across all training stages, including VAE pretraining and pocket alignment. CrossDocked poses are not independent unique experimentally measured binding examples; repeated ligands and related structures need to be tracked explicitly. The ten evaluation targets may or may not have been seen during alignment or fine-tuning—the manuscript does not establish this. This is an unresolved evaluation issue, not evidence that leakage occurred.
The transcriptomic processing also needs the number of distinct compounds, dose and exposure-time handling, replicate aggregation, quality filtering, and the gene representation used. These choices determine whether the model learns pharmacology or dataset-specific variation. A single cell line and ten targets provide a limited basis for broad generalization claims. Exact training-set novelty does not resolve any of these issues.
3. The ablations show a trade-off, not convincing multimodal synergy
The claim of a “significant synergistic effect” on p. 8 is not supported by the reported comparisons:
- In Table 1, the full model has better docking means than the pocket-only model on 2 of 10 targets, ties on 2, and is worse on 6.
- The full model never exceeds the profile-only model in QED: 0 wins, 3 ties, and 7 losses.
- On TP53, the profile-only model has better reported means on all three metrics: docking −5.75 versus −5.64, QED 0.74 versus 0.72, and SA 2.89 versus 2.94.
These comparisons do not prove that fusion is useless. They show that its benefit needs a more careful definition. Report a prespecified joint success criterion or Pareto analysis, together with per-target uncertainty, instead of describing a mixed trade-off as synergy.
The paper does not define whether the “±” values in Table 1 are standard deviations, standard errors, or variation across independent runs. Sampling 100 molecules per target does not measure training-seed variation. Please repeat training/sampling with independent seeds and report paired target-level effect sizes and confidence intervals. The significance of the small differences cannot be inferred from the current presentation.
There are also direct reporting inconsistencies. The EGFR discussion on p. 8 assigns −7.05 to the full model and calls it the best, whereas Table 1 assigns −7.01 to the full model and −7.05 to the profile-only model. The AURKB full-model score is −6.52 in the prose but −6.57 in Table 1. These should be reconciled before interpreting the ablation.
4. The comparisons do not isolate the proposed methodological contribution
The full model receives both modalities while the external baselines receive one. Such comparisons are useful for the practical system-level question, but they cannot by themselves distinguish an improved learning method from the benefit of additional information or different pretraining data.
The paper itself cites a closely related phenotype–target joint generation method, XMolRL/ExMolRL, in Section 4, but does not compare against it. Please include an appropriately matched comparison or explain why one is infeasible. A simple concatenation-based conditional generator, a fixed-weight fusion model, and a retrieval-and-docking baseline would also help establish what the learned gate and alignment actually contribute.
The technical components—SMILES VAE, contrastive alignment, hard-negative matching, latent diffusion, and gated fusion—are individually established. A valuable contribution could still come from their integration, but it requires clear evidence that this combination solves a previously unresolved problem. There are no separate ablations of the matching objective, contrastive objective, or learned gate. Moreover, Equation (3) applies binary classification to dot-product scores; the manuscript should explain what “BLIP-style” contributes beyond this relatively simple alignment procedure.
For the no-diffusion comparison, specify exactly how latent samples are produced once diffusion is removed. Otherwise, improved validity may reflect how well samples match the decoder's training distribution rather than a controlled demonstration of diffusion's specific advantages.
5. Docking and the therapeutic case study are overinterpreted
The docking protocol needs receptor identifiers and preparation, pocket definitions, protonation/tautomer handling, conformer generation, search settings, and treatment of failed molecules. It is particularly important to establish that the same redocking and filtering pipeline is applied to SMILES-generating and 3D-generating methods.
The selected examples in Figure 5 compare individual generated compounds with reference compounds after generating 100 candidates per target. Please state how those examples were selected and provide the full score distributions and success fractions. A selected favorable docking pose does not establish better affinity, selectivity, or therapeutic utility.
The designation “DrugBank-approved drugs” in Section 3.6 is also problematic. Inclusion in DrugBank is not itself regulatory approval. For example, published clinical evidence describes odanacatib development as discontinued after an increased stroke risk. Conversely, the statement that MTOR lacks approved reference drugs is incorrect as written: everolimus is an approved mTOR inhibitor. Its FKBP12-dependent mechanism may make it unsuitable for a particular docking setup, but that would be a structural/protocol exclusion, not an absence of approved drugs. Please verify the status and mechanism of every reference compound and revise the comparison accordingly.
These factual issues do not invalidate all generation results, but they weaken the clinical interpretation of the case study.
6. Alignment may confuse valid many-to-many associations with negatives
Equations (2)–(3) treat the paired molecule as positive and other batch molecules as negatives, with the most similar mismatch used as a hard negative. However, a pocket can bind multiple molecules, and multiple compounds can induce related expression profiles. The same compound can also appear under several perturbation conditions or in several complexes.
Please describe duplicate handling, batch construction, and whether known related/positive pairs are excluded from negative mining. This is especially relevant after pooling heterogeneous CrossDocked and LINCS records. I am not claiming that every off-diagonal pair is positive; the concern is that the current objective and data description do not address a predictable source of false negatives.